This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ACTC | |
|---|---|
| Name | ACTC |
ACTC
ACTC is a gene encoding the cardiac isoform of alpha-actin, a structural protein central to sarcomeric function in the heart. It is a focal point in studies linking molecular structure to cardiomyopathies and has been investigated across genetics, developmental biology, and translational medicine. Research on ACTC intersects with multiple landmark studies, institutions, and clinical trials that have shaped contemporary understanding of inherited cardiac disorders.
ACTC is the standard gene symbol used in human genetics nomenclature for the cardiac alpha-actin protein; historical aliases include alpha-cardiac actin and ACTC1 in some databases. The gene was characterized in projects involving the Human Genome Project, and its protein product was mapped in proteomic surveys by teams at Massachusetts General Hospital and Sanger Institute. Sequence comparisons were published alongside analyses from groups at Cold Spring Harbor Laboratory and Max Planck Society, which clarified orthology to actin genes studied in Xenopus laevis, Mus musculus, and Danio rerio.
The molecular cloning of ACTC traces to the late 20th century when laboratories at University of Cambridge and Harvard University isolated cardiac-specific actin transcripts using techniques refined at Stanford University. Early structural studies utilized methods from European Molecular Biology Laboratory collaborators and were contextualized by findings from the Nobel Prize-winning work on cytoskeletal proteins by researchers at Rockefeller University and Princeton University. Subsequent linkage studies at Cleveland Clinic and Johns Hopkins Hospital connected ACTC variants to familial cardiomyopathy pedigrees first described in cohorts assembled at Mayo Clinic and Mount Sinai Health System.
The ACTC protein integrates into the thin filament of the cardiac sarcomere, interacting with proteins characterized in structural complexes by teams at Wadsworth Center and University of Oxford. Its polymerization and interaction with myosin heavy chains were modeled using crystallographic data from European Synchrotron Radiation Facility and cryo-EM maps produced by groups at University of California, Berkeley and Massachusetts Institute of Technology. Functional assays performed at National Institutes of Health and Max Planck Institute for Heart and Lung Research demonstrated how ACTC binds tropomyosin and troponin subunits identified in studies at Yale University and Karolinska Institutet, modulating force generation during the cardiac cycle described in physiological research from University of Pennsylvania and Columbia University.
Pathogenic variants in ACTC have been implicated in hypertrophic cardiomyopathy, dilated cardiomyopathy, and left ventricular noncompaction, with genotype–phenotype correlations reported by consortia involving European Society of Cardiology and American Heart Association. Clinical cohorts at Cleveland Clinic and Royal Brompton Hospital documented presentations ranging from arrhythmia to sudden cardiac death, with variant interpretation frameworks influenced by guidelines from American College of Medical Genetics and Genomics. Reports from Great Ormond Street Hospital and Boston Children’s Hospital have detailed pediatric-onset cases, while population databases curated by Exome Aggregation Consortium and ClinVar aggregate variant data used by clinicians at University College London and Stanford Medicine.
Genetic testing panels for cardiomyopathy frequently include ACTC, employed in clinical laboratories accredited by College of American Pathologists and referenced in practice statements from European Society of Human Genetics. Functional characterization of novel ACTC variants has used induced pluripotent stem cell cardiomyocytes generated at University of Cambridge and gene-editing studies employing CRISPR platforms developed at Broad Institute and Wellcome Sanger Institute. Large-scale association studies incorporating ACTC variants were performed in biobanks such as UK Biobank and cohorts assembled by Framingham Heart Study, facilitating phenotype correlations analyzed with pipelines from National Center for Biotechnology Information and European Bioinformatics Institute.
Therapeutic strategies addressing ACTC-related disease have ranged from standard heart failure therapies used in trials at Ciccarone Center and Duke University Hospital to investigational allele-specific approaches developed at Genentech and academic centers including University of Michigan. Gene therapy proof-of-concept studies employing viral vectors were reported by teams at Children’s Hospital of Philadelphia and biopharma collaborations with Novartis; antisense and RNA-based modulation strategies drew on platforms from Ionis Pharmaceuticals and Moderna. Small-molecule modulators of sarcomeric function investigated in multicenter trials included compounds studied at Cytokinetics and translational programs at University of Oxford, while animal-model rescue experiments utilizing zebrafish and mouse lines were performed in laboratories at Scripps Research and Institut Pasteur.
Category:Human proteins